|Registry of biomedical companies:
  [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 689 active entries
1105 BA Amsterdam
Phone: +31-(0)20-566 7394
Fax: +31-(0)20-566 9272
Stock symbol: AMT (NYSE
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
AMT aspires to develop innovative gene therapies in order to significantly improve the lives of people affected by serious, debilitating diseases.
Our research is mainly focused on developing cures for inherited diseases that affect small numbers of patients (orphan diseases). In addition, several of our programs allow us to target selected non-orphan diseases associated with serious morbidity and / or high mortality that can be treated with gene therapy.
AMT’s research efforts are intended to fill an unmet medical need for treatment in the following areas:
- metabolic diseases
- liver diseases
- blood coagulation diseases
- diseases of the nervous system
- diseases of the eye
Gene therapy is a technique for correcting or replacing defective or missing genes that cause a disease. The advantage of gene therapy is its potential to cure a disease, rather than just treat the symptoms. With successful gene therapy, a long-lasting and possibly life-long effect can be accomplished in patients with just a single set of injections.
Last update of this entry: November 07, 2008
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.
Use the links below to share this article on the social bookmarking site of your choice.
Read more about social bookmarking at Wikipedia - Social Bookmarking